Study reveals mechanism behind failed remyelination in MS

NewsGuard 100/100 Score

Researchers from the University at Buffalo have made a discovery about remyelination that could lead to new treatment approaches for inflammatory diseases such as multiple sclerosis.

Myelinated nerve cells - by 3Dme Creative Studio

3Dme Creative Studio | Shutterstock

As described in the journal Cell Reports, the team found that in adult stem cells, the activation of a specific transcription factor induces pathological quiescence – where the stem cells become unable to respond to injury by generating myelin-forming oligodendrocytes.

Demyelination is a key feature of inflammatory conditions such as multiple sclerosis. The study describes the role of a transcription factor called PRRX1 in human oligodendrocyte progenitor cells.

Current studies into multiple sclerosis mainly focus on therapies that induce the differentiation of these progenitor cells. Here, Fraser Sim and colleagues focused on the possibility of new drugs that could block the pathological quiescence of the progenitors.

The idea that pathological quiescence of progenitors could prevent regeneration in MS is distinct from the current pre-clinical strategies making their way into trial.

Fraser Sim, Lead Researcher

The team found that activating the PRRX1 gene disrupted myelin repair by blocking proliferation of the oligodendrocyte progenitor.

The study showed that expression of PRRX1 caused cell cycle arrest and quiescence of oligodendrocyte progenitor cells, thereby disabling myelin production.

Sim and team also demonstrated that blocking PRRX1 expression prevented the negative effects of the proinflammatory cytokine interferon-y.

The expression of this transcription factor might be a viable target in inflammatory diseases such as multiple sclerosis, where interferon-y may prevent remyelination, says Sim.

The findings could pave the way for potential new therapeutic targets, as well as shedding light on the mechanism by which effective myelin repair and regeneration is prevented in MS.

The discovery that pathological quiescence is what causes this failed repair and regeneration of myelin will guide the team’s future studies.

We plan to pursue the idea that perhaps we could identify treatments for MS that work by overcoming pathological quiescence of oligodendrocyte precursors in demyelinating lesions that characterize this disease.”

Fraser Sim, Lead Researcher

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2019, June 19). Study reveals mechanism behind failed remyelination in MS. News-Medical. Retrieved on April 13, 2024 from

  • MLA

    Robertson, Sally. "Study reveals mechanism behind failed remyelination in MS". News-Medical. 13 April 2024. <>.

  • Chicago

    Robertson, Sally. "Study reveals mechanism behind failed remyelination in MS". News-Medical. (accessed April 13, 2024).

  • Harvard

    Robertson, Sally. 2019. Study reveals mechanism behind failed remyelination in MS. News-Medical, viewed 13 April 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.